CN109490457B - Application of a DA monoclonal antibody immunoaffinity column in the determination of domoic acid toxoid - Google Patents
Application of a DA monoclonal antibody immunoaffinity column in the determination of domoic acid toxoid Download PDFInfo
- Publication number
- CN109490457B CN109490457B CN201811395731.5A CN201811395731A CN109490457B CN 109490457 B CN109490457 B CN 109490457B CN 201811395731 A CN201811395731 A CN 201811395731A CN 109490457 B CN109490457 B CN 109490457B
- Authority
- CN
- China
- Prior art keywords
- column
- solution
- monoclonal antibody
- immunoaffinity column
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VZFRNCSOCOPNDB-AJKFJWDBSA-N domoic acid Chemical compound OC(=O)[C@@H](C)\C=C\C=C(/C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VZFRNCSOCOPNDB-AJKFJWDBSA-N 0.000 title description 45
- VZFRNCSOCOPNDB-UHFFFAOYSA-N domoic acid Natural products OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O VZFRNCSOCOPNDB-UHFFFAOYSA-N 0.000 title description 45
- VZFRNCSOCOPNDB-OXYNIABMSA-N isodomoic acid D Natural products CC(C=C/C=C(/C)C1CNC(C1CC(=O)O)C(=O)O)C(=O)O VZFRNCSOCOPNDB-OXYNIABMSA-N 0.000 title description 45
- 239000003053 toxin Substances 0.000 claims abstract description 25
- 231100000765 toxin Toxicity 0.000 claims abstract description 25
- 108700012359 toxins Proteins 0.000 claims abstract description 25
- 238000001514 detection method Methods 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 20
- 239000000523 sample Substances 0.000 claims description 17
- 239000007853 buffer solution Substances 0.000 claims description 16
- 150000002500 ions Chemical class 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 235000020637 scallop Nutrition 0.000 claims description 9
- 241000237509 Patinopecten sp. Species 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000010355 oscillation Effects 0.000 claims description 5
- 241000237502 Ostreidae Species 0.000 claims description 4
- 239000012491 analyte Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000007789 gas Substances 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 235000020636 oyster Nutrition 0.000 claims description 4
- 239000012488 sample solution Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 3
- 239000005695 Ammonium acetate Substances 0.000 claims description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
- 241000237536 Mytilus edulis Species 0.000 claims description 3
- 235000019257 ammonium acetate Nutrition 0.000 claims description 3
- 229940043376 ammonium acetate Drugs 0.000 claims description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 238000007599 discharging Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 239000004047 hole gas Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 2
- 238000001819 mass spectrum Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000002552 multiple reaction monitoring Methods 0.000 claims description 2
- 235000020638 mussel Nutrition 0.000 claims description 2
- 239000003761 preservation solution Substances 0.000 claims description 2
- 238000011002 quantification Methods 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 241000628923 Anadara sativa Species 0.000 claims 1
- 238000004458 analytical method Methods 0.000 abstract description 8
- 238000000746 purification Methods 0.000 abstract description 7
- 238000012216 screening Methods 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000011159 matrix material Substances 0.000 abstract description 3
- 238000011084 recovery Methods 0.000 abstract description 3
- 238000004904 shortening Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 238000011725 BALB/c mouse Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 235000015170 shellfish Nutrition 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000000967 suction filtration Methods 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000008098 formaldehyde solution Substances 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007974 sodium acetate buffer Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000237503 Pectinidae Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000991 chicken egg Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000237528 Arcidae Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 239000000238 shellfish toxin Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及一种免疫亲和柱，尤其是涉及一种DA单克隆抗体免疫亲和柱制备方法，通过筛选出对DA毒素具特异性的抗体从而制得一种高性能、强识别的DA单克隆抗体免疫亲和柱，得到的DA单克隆抗体免疫亲和柱可应用于不同海洋生物中DA毒素的分析测定，有效解决前处理中样品净化不理想的问题，并减少样品基质干扰，缩短分析时间，提高方法回收率，填补免疫亲和技术在DA毒素检测领域的空白。本发明还提供了一种DA单克隆抗体免疫亲和柱的应用。The invention relates to an immunoaffinity column, in particular to a method for preparing a DA monoclonal antibody immunoaffinity column. By screening out antibodies specific to DA toxins, a DA monoclonal with high performance and strong recognition is prepared. The cloned antibody immunoaffinity column, and the obtained DA monoclonal antibody immunoaffinity column can be used for the analysis and determination of DA toxins in different marine organisms, effectively solving the problem of unsatisfactory sample purification in pretreatment, reducing sample matrix interference and shortening the analysis. time, improve method recovery, and fill the gap of immunoaffinity technology in the field of DA toxin detection. The invention also provides the application of a DA monoclonal antibody immunoaffinity column.
Description
Technical Field
The invention relates to an immunoaffinity column, in particular to an application of a DA monoclonal antibody immunoaffinity column in determination of chondroacronic acid toxins.
Background
The memory-deficient shellfish poison (ASP) is toxin secreted by diatom in the red tide, and Domoic Acid (DA), a main active ingredient, is a nervous amino acid toxin. The toxin was first discovered in 1987 in the toxic death event caused by eating common mussels on the east coast of the island of the Edward prince, Canada. The intoxication is manifested as abdominal pain, diarrhea, vomiting, severe headache, memory loss, confusion, coma, etc. It was found that DA is mainly produced by the columns of rhomboidium. When the alginic acid content in the shellfish tissue reaches 40mg/kg, the shellfish tissue can cause poisoning of consumers, when 150mg/kg, the shellfish tissue has death risk, the maximum tolerable limit of human beings by eating is 20mg/kg, Canada firstly establishes a safety limit standard of 20 mu g/g shellfish meat, and Europe and Japan also successively list the toxin as a shellfish conventional detection project. The research of China on DA still belongs to the starting stage, and an effective detection means and a monitoring network are not available. Although the report of detecting DA in China is rare at present, a plurality of toxigenic rhombohedral algae strains are detected in China coastal regions. Considering that the toxin has high toxicity, quick response and no antidote, the development of detection research on DA toxin in marine organisms is very important for ensuring the safety of aquatic products and the health of human bodies.
An immunoaffinity column (IAC) is a novel chromatographic column based on antigen-antibody reaction, is manufactured by utilizing the affinity recognition and reversible binding characteristics of a specific antibody to a target toxin, and has high selection specificity and good adsorption and purification performance. At present, no related report of using immunoaffinity column as pretreatment purification means to detect DA toxin exists in China.
Disclosure of Invention
The invention aims to provide a preparation method of a DA monoclonal antibody immunoaffinity column, the prepared immunoaffinity column has the characteristics of high performance and strong recognition by screening out an antibody with specificity to DA toxin, can be applied to analysis and determination of DA toxin in different marine organisms, effectively solves the problem of unsatisfactory purification of a sample in pretreatment, reduces sample matrix interference, shortens analysis time, improves method recovery rate, and fills the blank of the immunoaffinity technology in the field of DA toxin detection.
The invention also provides an application of the DA monoclonal antibody immunoaffinity column.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention relates to a preparation method of a DA monoclonal antibody immunoaffinity column, which comprises the following steps:
(1) synthetic immunogens
10mg of bovine serum albumin, 2mL of 0.05M sodium acetate buffer solution with pH7.4, 1mg of domoic acid and 60 mu L of formaldehyde solution with the mass concentration of 37% are sequentially added into a small flask, mixed uniformly, stirred at 37 ℃ for 48 hours, dialyzed with 0.1M PBS buffer solution with pH7.3 at 4 ℃ for 3 days, and changed every day for 2 times to obtain immunogen DA-BSA.
(2) Synthetic assay antigen
10mg of chicken egg white albumin, 2mL of 0.05M sodium acetate buffer solution with pH7.4, 1mg of domoic acid and 60 mu L of formaldehyde solution with the mass concentration of 37% are sequentially added into a small flask, mixed uniformly, stirred at 37 ℃ for 48 hours, dialyzed by 0.1M PBS buffer solution with pH7.3 at 4 ℃ for 3 days, and changed every day for 2 times to obtain the original DA-OVA for detection.
(3) Monoclonal antibody preparation and purification
Taking 5 female Balb/c mice with the age of 6-8 weeks, injecting DA-BSA (Dada-bovine serum albumin) 20 mu g/mouse subcutaneously at the back, starting to strengthen the immunity after immunizing for 4 weeks, and strengthening the immunity for 1 time every 2 weeks; in the primary immunization, emulsifying immunogen DA-BSA and an isovolume Freund's complete adjuvant, and emulsifying immunogen DA-BSA and an isovolume Freund's incomplete adjuvant in the boosting immunization, wherein the immunization dose and the immunization mode are unchanged;
after 10 days of 2-time boosting immunization, taking tail venous blood of mice for detection, coating a detection source DA-OVA, detecting the titer of serum by using an indirect competitive ELISA method, selecting a BALB/c mouse with the highest titer for preparing hybridoma, boosting the abdominal cavity of the mouse once 3 days before fusion, taking the spleen cell of the BALB/c mouse with the highest titer to fuse with a myeloma cell Sp2/0, and screening to obtain the hybridoma;
BALB/c mice were intraperitoneally injected with 0.5mL liquid paraffin for sensitization, and 8 days later, mice were intraperitoneally injected with 1X 107And (3) extracting ascites from the abdominal cavity of the mouse by using a syringe after 10 days, extracting the ascites for 1 time every 1 day, centrifuging, collecting supernate, purifying the supernate by adopting a saturated ammonium sulfate method, and further purifying by adopting a protein affinity chromatography to obtain the DA monoclonal antibody.
(4) Affinity column preparation
Weighing 0.5g of CNBr activated sepharose 4B dry powder, swelling the sepharose 4B dry powder by using 100mL of 1M HCl solution, and washing; then washing with 100mL of coupling buffer solution to obtain gel;
taking 1.5mL of the swelled gel, adding 1.5mL of 10mg/mL DA monoclonal antibody, carrying out oscillation coupling reaction at room temperature for 2h, carrying out suction filtration, washing the gel with 30mL of coupling buffer solution, carrying out suction filtration, adding 10mL of blocking buffer solution, carrying out oscillation reaction at room temperature for 2h, carrying out suction filtration, washing the gel with 100mL of 0.01M PBS buffer solution with pH7.3, transferring the gel into a 5mL column tube, adding 0.01M PBS solution with the mass concentration of 0.05% of thimerosal and 0.05% of bovine serum albumin respectively and storing the gel at 2-8 ℃.
Preferably, in step (4), the formulation of the coupling buffer is: 0.1 mol. L-1 NaHCO3，0.5 mol·L-1 NaCl，pH8.3。
Preferably, in step (4), the formulation of the blocking buffer is: 0.1 mol. L-1 Tris-HCl，pH 8.0。
An application of DA monoclonal antibody immunoaffinity column in determination of chondroacronic acid toxin is disclosed.
Therefore, the invention has the following beneficial effects: the DA toxin immunoaffinity column with high performance and strong recognition is prepared by screening out the antibody with specificity to the DA toxin, and the obtained DA toxin immunoaffinity column can be applied to analysis and determination of the DA toxin in different marine organisms, so that the problem of unsatisfactory sample purification in pretreatment is effectively solved, the interference of a sample matrix is reduced, the analysis time is shortened, the recovery rate of the method is improved, and the blank of the immunoaffinity technology in the field of DA toxin detection is filled.
Detailed Description
The invention is further described below by means of specific embodiments.
In the present invention, all percentages are by weight unless otherwise specified, all equipment and materials are commercially available or commonly used in the industry, and the methods in the following examples are conventional in the art unless otherwise specified.
Instrument and reagent
ACQUITY ultra high performance liquid chromatography-tandem Mass spectrometer Xevo TQ-S (Waters, USA); MS2 vortex mixer (IKA, germany); nitrogen blow dryer (organo matio corporation, usa); centrifuge5810 high speed Centrifuge (Eppendorf, germany); 12 channel solid phase extraction device (supelco, usa).
Domoic Acid (DA) standard (purity ≥ 98.0%, canadian national research council); acetonitrile, methanol (chromatographically pure, Merck, germany); ammonium acetate, formic acid (Sigma, usa); disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, and ammonia water (Shanghai national drug group); the experimental water is ultrapure water.
(II) preparation of PBS buffer solution
2.18g of sodium dihydrogen phosphate dihydrate, 12.90g of disodium hydrogen phosphate dodecahydrate and 8.50g of sodium chloride are weighed respectively, dissolved by water and fixed to 1000 mL.
(III) 25. mu.g/mL Domoic Acid (DA) standard solution
Accurately transferring a proper amount of domoic acid standard solution, diluting with methanol to a constant volume of 50mL, and storing at-20 ℃ in the dark for 3 months.
Examples
(a) Synthetic immunogens
Adding 10mg of bovine serum albumin, 2mL of 0.05M sodium acetate buffer solution with pH of 7.4, 1mg of domoic acid and 60 mu L of formaldehyde solution with the mass concentration of 37% into a small flask in sequence, mixing uniformly, stirring at 37 ℃ for 48h, dialyzing with 0.1M PBS buffer solution with pH of 7.3 at 4 ℃ for 3 days, and changing the solution 2 times every day to obtain immunogen DA-BSA;
(b) synthetic assay antigen
Sequentially adding 10mg of chicken egg white albumin, 2mL of 0.05M sodium acetate buffer solution with pH7.4, 1mg of domoic acid and 60 mu L of formaldehyde solution with the mass concentration of 37 percent into a small flask, uniformly mixing, stirring at 37 ℃ for 48h, dialyzing by using 0.1M PBS buffer solution with pH7.3 at 4 ℃ for 3 days, and changing the solution 2 times every day to obtain the original DA-OVA for detection;
(c) monoclonal antibody preparation and purification
Taking 5 female Balb/c mice with the age of 6-8 weeks, injecting DA-BSA (Dada-bovine serum albumin) 20 mu g/mouse subcutaneously at the back, starting to strengthen the immunity after immunizing for 4 weeks, and strengthening the immunity for 1 time every 2 weeks; in the primary immunization, emulsifying immunogen DA-BSA and an isovolume Freund's complete adjuvant, and emulsifying immunogen DA-BSA and an isovolume Freund's incomplete adjuvant in the boosting immunization, wherein the immunization dose and the immunization mode are unchanged;
after 10 days of 2-time boosting immunization, taking tail venous blood of mice for detection, coating a detection source DA-OVA, detecting the titer of serum by using an indirect competitive ELISA method, selecting a BALB/c mouse with the highest titer for preparing hybridoma, boosting the abdominal cavity of the mouse once 3 days before fusion, taking the spleen cell of the BALB/c mouse with the highest titer to fuse with a myeloma cell Sp2/0, and screening to obtain the hybridoma;
BALB/c mice were intraperitoneally injected with 0.5mL liquid paraffin for sensitization, and 8 days later, mice were intraperitoneally injected with 1X 107Extracting ascites from the abdominal cavity of the mouse by using an injector after 10 days, then extracting the ascites for 1 time every 1 day, centrifuging, collecting supernate, purifying the supernate by adopting a saturated ammonium sulfate method, and further purifying by using a protein affinity chromatography to obtain a DA monoclonal antibody;
(d) affinity column preparation
Weighing 0.5g of CNBr activated sepharose 4B dry powder, swelling the sepharose 4B dry powder by using 100mL of 1M HCl solution, and washing; then washing with 100mL of coupling buffer solution to obtain gel, wherein the formula of the coupling buffer solution is as follows: 0.1 mol. L-1 NaHCO3，0.5 mol·L-1NaCl，pH8.3；
Taking 1.5mL of the swelled gel, adding 1.5mL of 10mg/mL DA monoclonal antibody, oscillating at room temperature for coupling reaction for 2h, filtering, and washing the gel with 30mL of coupling buffer solution, wherein the formula of the coupling buffer solution is as follows: 0.1 mol. L-1 NaHCO3，0.5 mol·L-1NaCl, pH8.3, suction filtration, and the addition of 10mL of blocking buffer, the formulation of the blocking buffer is: 0.1 mol. L-1Tris-HCl, pH8.0, room temperature oscillation reaction for 2h, suction filtration, then 100mL PBS buffer solution of 0.01M, pH7.3 to wash the gel, and transfer to 5mL column tube, add PBS solution of 0.01M, pH7.3 containing the mass concentration of 0.05% thimerosal, 0.05% bovine serum albumin, respectively, store at 2-8 ℃.
The application method of the DA monoclonal antibody immunoaffinity column obtained by the invention in determination of chondroacronic acid toxins comprises the following steps:
(1) sample pretreatment: accurately weighing 2.00g of a fully homogenized sample into a 50mL centrifuge tube with a plug, adding 8mL of 75% methanol aqueous solution in volume concentration, carrying out vortex oscillation for 2min, carrying out ultrasonic extraction for 10min, centrifuging at 7000r/min for 5min, and transferring the supernatant into another 50mL centrifuge tube to obtain a primary extract; adding 8mL of 75% methanol aqueous solution into the residual residue, and repeatedly extracting once to obtain a secondary extracting solution; mixing the primary extract and the secondary extract, and diluting to a constant volume of 20mL to obtain an extract; transferring 1mL of the extracting solution into another 50mL of centrifugal tube, and adding 5mL of PBS buffer solution for dilution to obtain a sample solution to be purified;
(2) purifying the immunoaffinity column: taking a DA monoclonal antibody immunoaffinity column, removing an affinity column plug after the DA monoclonal antibody immunoaffinity column is recovered to room temperature, discharging a preservation solution in the column, and then loading a sample solution; after the sample loading is finished, eluting the affinity column by using 6mL of methanol water solution with volume concentration of 50%, squeezing out residual liquid in the column, discarding all effluent liquid, eluting by using 3mL of methanol solution containing ammonia water with mass concentration of 2%, drying the collected eluent by using nitrogen at 50 ℃, dissolving by using 1mL of initial mobile phase with constant volume, filtering by using a 0.22 mu m filter membrane, and then supplying liquid chromatography-mass spectrometry for analysis;
the liquid chromatography conditions were: a chromatographic column: ACQUITY UPLC BEH C18A column (2.1 mm x 50 mm, 1.7 μm); the sample injection volume is 2 mu L; the temperature of the sample chamber is 10 ℃; the column temperature is 40 ℃; the flow rate is 0.2 mL/min; mobile phase a was acetonitrile and B was a 2mmol/L ammonium acetate solution containing 0.1% formic acid, gradient elution: 0-1.0 min, 90% A; 1.0-3.0 min, 90-10% A; 3.0-4.0 min, 10% A; 4.0-4.1 min, 10% -90% A; 4.1-5.5 min, 90% A;
the mass spectrum conditions are as follows: electrospray ion source, positive ion scanning (ESI-); the detection mode is as follows: multiple Reaction monitoring mode (MRM); capillary voltage: 3.0 kV; ion source temperature: 150 ℃; desolventizing gas temperature: 600 ℃; taper hole gas flow: 150L/h; desolventizing agent gas flow: 1000L/h; taper hole voltage: 12V; collision energy: 16 eV; analyte qualitative ion pair:m/z 312.2 >248.2; analyte quantification ion pair:m/z 312.2 > 266.2。
59 parts of 5 varieties of coastal cities, namely mussels, ark shells, scallops and oysters are analyzed and detected by the method, and the obtained detection results are shown in table 1. The DA detection rate is 10%, the detection rate comprises 5 batches of scallops and 1 batch of oysters, the scallop detection rate is highest, and the DA pollution level is different from 0.9 to 11.8 mug/g; the oyster detection rate is 7%, and the DA content is 0.07 mug/g.
TABLE 1 contamination level of DA in Positive samples
| Variety of (IV) C | DA concentration (μ g/g) |
| Scallop | 11.8 |
| Scallop | 14.9 |
| Scallop | 0.7 |
| Scallop | 9.3 |
| Scallop | 0.9 |
| Oyster shell | 0.07 |
Therefore, the DA monoclonal antibody immunoaffinity column obtained by the invention has the characteristics of high performance and strong identification, and can completely meet the analysis and determination requirements of DA toxin in marine organisms.
The above-described embodiments are only preferred embodiments of the present invention, and are not intended to limit the present invention in any way, and other variations and modifications may be made without departing from the spirit of the invention as set forth in the claims.
Claims (1)
1. The application of the DA monoclonal antibody immunoaffinity column in determination of chondroacronic acid toxins is characterized in that the specific application method is as follows:
(a) sample pretreatment: accurately weighing 2.00g of a fully homogenized mussel tissue sample, arca subcrenata tissue sample, scallop tissue sample or oyster tissue sample in a 50mL centrifuge tube with a plug, adding 8mL of 75% methanol aqueous solution, carrying out vortex oscillation for 2min, carrying out ultrasonic extraction for 10min, centrifuging at 7000r/min for 5min, and transferring the supernatant to another 50mL centrifuge tube to obtain a primary extract; adding 8mL of 75% methanol aqueous solution into the residual residue, and repeatedly extracting once to obtain a secondary extracting solution; mixing the primary extract and the secondary extract, and diluting to a constant volume of 20mL to obtain an extract; transferring 1mL of the extracting solution into another 50mL of centrifugal tube, and adding 5mL of PBS buffer solution for dilution to obtain a sample solution to be purified;
(b) purifying the immunoaffinity column: taking a DA monoclonal antibody immunoaffinity column, removing an affinity column plug after the DA monoclonal antibody immunoaffinity column is recovered to room temperature, discharging a preservation solution in the column, and then loading a sample solution; after the sample loading is finished, eluting the affinity column by 6mL of methanol water solution with volume concentration of 50%, squeezing out residual liquid in the column, discarding all effluent liquid, eluting by 3mL of methanol solution containing ammonia water with mass concentration of 2%, drying the collected eluent by nitrogen at 50 ℃, dissolving by 1mL of initial mobile phase with constant volume, filtering by a filter membrane, and analyzing by liquid chromatography-mass spectrometry; the liquid chromatography conditions were: a chromatographic column: ACQUITY UPLC BEH C18The column specification is 2.1mm multiplied by 50 mm, 1.7 mu m; the sample injection volume is 2 mu L; the temperature of the sample chamber is 10 ℃; the column temperature is 40 ℃; the flow rate is 0.2 mL/min; mobile phase a was acetonitrile and B was a 2mmol/L ammonium acetate solution containing 0.1% formic acid, gradient elution: 0-1.0 min, 90% A; 1.0-3.0 min, 90-10% A; 3.0-4.0 min, 10% A; 4.0-4.1 min, 10% -90% A; 4.1-5.5 min, 90% A; the mass spectrum conditions are as follows: electrospray ion source, positive ion scanning; the detection mode is as follows: a multiple reaction monitoring mode; capillary voltage: 3.0 kV; ion source temperature: 150 ℃; desolventizing gas temperature: 600 ℃; taper hole gas flow: 150L/h; desolventizing agent gas flow: 1000L/h; taper hole voltage: 12V; collision energy: 16 eV; analyte qualitative ion pair:m/z 312.2 >248.2; analyte quantification ion pair:m/z 312.2 > 266.2。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811395731.5A CN109490457B (en) | 2018-11-22 | 2018-11-22 | Application of a DA monoclonal antibody immunoaffinity column in the determination of domoic acid toxoid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811395731.5A CN109490457B (en) | 2018-11-22 | 2018-11-22 | Application of a DA monoclonal antibody immunoaffinity column in the determination of domoic acid toxoid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109490457A CN109490457A (en) | 2019-03-19 |
| CN109490457B true CN109490457B (en) | 2021-06-22 |
Family
ID=65697356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811395731.5A Active CN109490457B (en) | 2018-11-22 | 2018-11-22 | Application of a DA monoclonal antibody immunoaffinity column in the determination of domoic acid toxoid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109490457B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102680693A (en) * | 2012-05-18 | 2012-09-19 | 上海交通大学 | Domoic acid collaurum immunochromatographic test strip and preparation method thereof |
| CN104391061A (en) * | 2014-10-31 | 2015-03-04 | 浙江省海洋水产研究所 | Method for determining tetrodotoxin in marine organisms by utilizing immunoaffinity column purification-liquid phase chromatography-tandem mass spectrometry |
| EP2960650A1 (en) * | 2013-02-19 | 2015-12-30 | Universidad de Alcalá | Analytical immunosensor device and method for constructing same |
-
2018
- 2018-11-22 CN CN201811395731.5A patent/CN109490457B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102680693A (en) * | 2012-05-18 | 2012-09-19 | 上海交通大学 | Domoic acid collaurum immunochromatographic test strip and preparation method thereof |
| EP2960650A1 (en) * | 2013-02-19 | 2015-12-30 | Universidad de Alcalá | Analytical immunosensor device and method for constructing same |
| CN104391061A (en) * | 2014-10-31 | 2015-03-04 | 浙江省海洋水产研究所 | Method for determining tetrodotoxin in marine organisms by utilizing immunoaffinity column purification-liquid phase chromatography-tandem mass spectrometry |
Non-Patent Citations (3)
| Title |
|---|
| Determination of Domoic Acid in Japanese Mussels by Enzyme Immunoassay;KENTARO KAWATSU et al.;《JOURNAL OF AOAC INTERNATIONAL》;20001231;第83卷(第6期);第1384-1386页 * |
| Immunoaffinity Chromatography Purification and Ultrahigh Performance Liquid Chromatography Tandem Mass Spectrometry Determination of Tetrodotoxin in Marine Organisms;Xiaojun Zhang et al.;《Journal of Agricultural and Food Chemistry》;20150310;第63卷;3129-3134页 * |
| Production and characterization of a monoclonal antibody against domoic acid and its application to enzyme immunoassay;Kentaro Kawatsu et al.;《Toxicon》;19991231;第37卷;第1579-1582页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109490457A (en) | 2019-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101413955B (en) | ELISA test box for detecting zearalenone and preparing and detecting method thereof | |
| CN102967709B (en) | Detect enzyme linked immunological kit and the application thereof of zearalenone medicine | |
| CN104391061B (en) | The method of tetraodotoxin in immune affinity column purification-liquid chromatography tandom mass spectrometry determination sea life | |
| CN108727502A (en) | A kind of Fab segment preparation method and applications of lefofloxacin antibody | |
| CN100465644C (en) | Microcystin ELISA Kit | |
| CN109374809B (en) | A method for the determination of domoic acid toxoid by immunoaffinity column purification-liquid chromatography-tandem mass spectrometry | |
| CN109490457B (en) | Application of a DA monoclonal antibody immunoaffinity column in the determination of domoic acid toxoid | |
| CN103170309A (en) | Ractopamine antibody immunoaffinity chromatographic column and application thereof | |
| WO2018095254A1 (en) | Monoclonal cell line c4 capable of secreting monoclonal antibody recognizing methylene blue and application thereof | |
| CN100570323C (en) | A ractopamine immunoaffinity column and its preparation method and application | |
| WO2018103630A1 (en) | Hybridoma cell strain c1 for secreting anti-paromomycin monoclonal antibody and use thereof | |
| CN113637642B (en) | Hybridoma cell strain secreting chlorfenapyr monoclonal antibody and application thereof | |
| CN111909903B (en) | Zilpaterol monoclonal antibody hybridoma cell strain and application thereof | |
| CN114752568B (en) | Furosemide monoclonal antibody, hybridoma cell strain and application | |
| CN112480167B (en) | Isocarbophos hapten, artificial antigen and antibody as well as preparation method and application thereof | |
| CN101907624A (en) | A rhodamine 6G immunoaffinity chromatography column and its preparation method and application | |
| US4900664A (en) | Reagent for detection and measurement of acetaldehyde-protein condensates in a fluid, together with its preparation and method of use | |
| CN1322010C (en) | Method for preparing polyclonal antibody of ascites from anti aflatoxin B1 of rat | |
| CN104672322B (en) | A kind of phenol synthesizing artificial antigen | |
| JP3091974B2 (en) | 8-Hydroxy-2'-deoxyguanosine monoclonal antibody, method for producing the same, and hybrid cell producing monoclonal antibody | |
| CN118724807B (en) | A decoquinate hapten, antigen, antibody and preparation and application thereof | |
| CN103706331A (en) | Immunoaffinity column for quickly purifying and enriching cimaterol as well as preparation method and application of immunoaffinity column | |
| CN114317452B (en) | Naphthylacetic acid monoclonal antibody, hybridoma cell strain and application | |
| CN103145566B (en) | Artificial ractopamine antigen, preparation method thereof and application | |
| CN1979158A (en) | Beta analeptic clenbuterol immune affinity column, its preparing method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |